Oligonucleotide– tag –
-
Imperial College Develops Prostate-Targeted mRNA Nanogels, Overcoming Liver Accumulation in Cancer Therapy
Imperial College London UK Overview Researchers at Imperial College London have developed prostate-targeted degradable polymer nanogels for mRNA delivery in prostate cancer treatment. This innovation overcomes the challenge of tissue-spe... -
Dove Medical Press Reviews Exosome-Inspired Nanocarriers: Next-Gen Drug Delivery for Cancer Therapy
Dove Medical Press UK Overview Dove Medical Press published a review on exosomes as next-generation bio-derived drug delivery systems for cancer therapy. The review emphasizes exosomes' natural ability to cross biological barriers and th... -
World Economic Forum Names Exosome DDS and Personalized mRNA Cancer Vaccines as Top Emerging Technologies for 2026
World Economic Forum Global Overview The World Economic Forum's 'Top 10 Emerging Technologies of 2026' report details exosome drug delivery systems (DDS) and personalized mRNA cancer vaccines as key innovations. Exosome DDS leverages the... -
Exosome Drug Delivery and Personalized mRNA Cancer Vaccines Emerge as Top Tech Trends for 2026, Showing Promise in Clinical Trials
Today Tech Times Global Overview Today Tech Times reports that exosome drug delivery systems (DDS) and personalized mRNA cancer vaccines are leading technology trends for 2026. Exosome DDS is the focus of over 200 ongoing clinical trials... -
Beyond Vaccines: mRNA Technology Expands into Personalized Cancer, Protein Replacement, and Regenerative Medicine
Unknown Global Overview mRNA technology is rapidly expanding beyond vaccines into new medical applications, including personalized cancer vaccines, protein replacement therapies, and regenerative medicine. Ongoing research is actively fo... -
Self-Amplifying RNA (saRNA) Gains Ground Over Conventional mRNA, Proving Superiority Across Diverse Therapeutics; First COVID-19 Vaccines Approved in Japan and EU
TriLink BioTechnologies USA Overview Self-amplifying RNA (saRNA) is gaining traction over conventional mRNA due to its ability to amplify transcripts inside cells, producing more protein per molecule and sustaining expression for days to... -
2026 RNA Therapeutics Transformation: FDA Approves ASO Olezarsen, siRNA Fitusiran & Plozasiran, Ushering in Diverse Nucleic Acid Era
MiraScope Unknown Overview The year 2026 marks a significant transformation in RNA therapeutics, with multiple approvals solidifying antisense oligonucleotide (ASO) and siRNA therapies as established treatment platforms. Ionis Pharmaceut... -
LNP-Delivered Multi-Specific CAR mRNA Engineering Platform Advances: Enables Controllable In Vivo CAR Expression, Overcomes Autologous Cell Manufacturing Challenges
Ace Therapeutics Unknown Overview A lipid nanoparticle (LNP)-formulated messenger RNA (mRNA) therapy platform is advancing as a novel strategy to generate CAR-expressing immune cells in vivo. This approach allows for transient and contro... -
Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients
Insight, China's Pharmaceutical Industry China Overview Ribo Life Science's siRNA therapy, vortosiran (BD4059), has received clinical trial approval from the EMA for stroke prevention in atrial fibrillation (SPAF) patients. Vortosiran is... -
LNP-Mediated Gene Therapy to Correct ACTA2 Mutations Shows Promise: Reduces Stroke-Related Mortality, Offers Re-dosability & Lower Costs Over Viral Vectors
MSMDS.org USA Overview A novel lipid nanoparticle (LNP)-based gene therapy strategy is under development to correct ACTA2 mutations in vascular smooth muscle cells. This approach offers significant advantages over viral vectors, includin...
